Targeted delivery of anticancer drugs to tumor vessels by use of liposomes modified with a peptide identified by phage biopanning with human endothelial progenitor cells
- 1 May 2017
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 524 (1-2) , 364-372
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (JSPS)
This publication has 33 references indexed in Scilit:
- Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499Journal of Controlled Release, 2014
- Doxil® — The first FDA-approved nano-drug: Lessons learnedJournal of Controlled Release, 2012
- Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248Molecular Cancer Therapeutics, 2008
- Antineovascular therapy with angiogenic vessel‐targeted polyethyleneglycol‐shielded liposomal DPP–CNDACCancer Science, 2008
- Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung MetastasisScience, 2008
- Identification and Clinical Significance of Circulating Endothelial Progenitor Cells in Human Non–Small Cell Lung CancerCancer Research, 2006
- Anti‐neovascular therapy by liposomal DPP‐CNDAC targeted to angiogenic vesselsFEBS Letters, 2002
- Genes Expressed in Human Tumor EndotheliumScience, 2000
- Tumor angiogenesis—new drugs on the blockNature Biotechnology, 1999
- Isolation of Putative Progenitor Endothelial Cells for AngiogenesisScience, 1997